Before you read the misinformation, read the following:
1. Vaccines will not be discontinued.
The EU Strategy on COVID-19 Therapeutics aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use.
The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe’s health systems.
The Strategy, which focuses on the treatment of patients with COVID-19, works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.
The EU Vaccines Strategy
Objectives of the strategy
On 17 June 2020, the European Commission presented the EU Vaccines Strategy to accelerate the development, manufacturing and deployment of vaccines against COVID-19.
With the vaccines strategy, the Commission supported efforts to make the process more efficient, resulting in this timeframe being reduced to less than one year for most vaccines.
The objectives of the EU Vaccines Strategy are:
- to ensue the quality, safety and efficacy of vaccines
- to secure timely access to vaccines for Member States and their population while leading the global solidarity effort
- to ensure equitable and affordable access for all in the EU to an affordable vaccine as early as possible
- to make sure that preparations are made in EU countries regarding the roll-out of safe and effective vaccines, addressing transportation and deployment needs, and identifying priority groups
The vaccine strategy should act as a reference point for Member States when formulating their national vaccination strategies.
Safe and effective vaccines started to be distributed in the EU by the end of 2020, following strict authorisation procedures and the highest safety standards.
To date, 4 safe and effective vaccines against COVID-19 have been authorised by the Commission for use in the EU following positive scientific recommendations by the European Medicines Agency
2. The Pasteur Institute studied Ivermectin and Covid-19 in animals and not people. It recommends trial studies of Ivermectin and Covid-19 in people.
Ivermectin alleviates Covid-19 symptoms in an animal model
Press release 2021.07.12
Since the start of the COVID-19 pandemic, various therapeutic approaches have been explored to tackle the disease. Scientists from the Institut Pasteur have shown that ivermectin, a drug used commercially as an antiparasitic treatment, offers protection from COVID-19 symptoms in an animal model. The scientists observed that taking ivermectin was associated with reduced inflammation in the respiratory tract and an alleviation of the related symptoms. The treatment is also associated with protection against loss of smell. However, the results do not show any impact on the viral replication of SARS-CoV-2. The findings of the study suggest that ivermectin could be considered as a potential therapeutic agent for COVID-19. These results were published in the journal EMBO Molecular Medicine on July 12, 2021.
“Our results represent a significant breakthrough, demonstrating that ivermectin belongs to a new category of COVID-19 drugs in an animal model. This research opens up new avenues for the development of more effective COVID-19 treatments in humans,” concludes Hervé Bourhy, Head of the Lyssavirus Epidemiology and Neuropathology Unit and last author of the study.
3. The European Union has approved 5 therapies but Ivermectin is not one of them.
The EU Strategy on COVID-19 Therapeutics delivers today its first outcome, with the announcement of the first portfolio of five therapeutics that could soon be available to treat patients across the EU. Four of these therapeutics are monoclonal antibodies under rolling review by the European Medicines Agency. Another one is an immunosuppressant, which has a marketing authorisation that could be extended to include the treatment of COVID-19 patients.
The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy. The products are:
A new COVID-19 indication for existing medicines:
- baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment
Newly developed monoclonal antibodies under rolling review – a regulatory tool to speed up the assessment of a promising medicine during a public health emergency:
- combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review
- combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review
- regdanvimab from Celltrion: under rolling review
- sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review
This is the misleading information received via WhatsApp.
TO BE DISTRIBUTED TO ALL who do not want to be “vaccinated”. All vaccines will no longer be justified after 10/20/2021: Information Reviewed. The European Union has approved 5 therapies (https://ec.europa.eu/commission/presscorner/detail/fr/ip_21_3299) that will be available in all hospitals of the Member States for the treatment of Covid. These therapies are approved by Decree of the European Council (European Parliament) and will be operational from 1/10, therefore they will be gradually distributed around 20/10. The vaccines have been approved on a “provisional trial” basis. However, since there is a prescription requirement for these 5 new drugs by decree, the use of the vaccine will be discontinued. Therefore, we understand why all the states said “between September it is necessary that …”. They already knew everything. You have to be patient. Do not accept blackmail. Be patient. Now that ivermectin is re-approved, there is no need for a vaccine. Excellent news. The Pasteur Institute recognizes the efficacy of ivermectin. A single dose could wipe out all SARS covid-19 genetic material in some people. Good read and share. Good news: Ivermectin is now scientifically recognized by researchers at the Pasteur Institute in France as an effective drug, in prophylaxis and treatment of covid-19. The results of their studies were published July 12, 2021, in the journal EMBO Molecular Medicine. An analysis of the results of other research published in the American Journal of Therapeutics strongly urges overriding health authority guidelines and including ivermectin as a standard of care. Macron’s government knew about this … Stay healthy and feel free to cheer people who don’t want to get vaccinated 🥬